Immatics NV - ESG Rating & Company Profile powered by AI
This report of Immatics NV leverages intelligence from across the internet as well as from public filings by Immatics NV. If you work at Immatics NV and you would like to use your ESG rating, please get in touch. Alternative corporations in the scoring industry group for Immatics NV are displayedin the table.
Immatics NV in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.8; made up of an environmental score of 1.6, social score of 3.2 and governance score of 6.7.
3.8
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 1476 | Philogen SpA | 3.9 | Medium |
| 1476 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | 3.9 | Medium |
| 1512 | Immatics NV | 3.8 | Medium |
| 1512 | Ampio Pharmaceuticals Inc | 3.8 | Medium |
| 1512 | Abeona Therapeutics Inc | 3.8 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Immatics NV have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Immatics NV disclose current and historical energy intensity?
Sign up for free to unlockDoes Immatics NV report the average age of the workforce?
Sign up for free to unlockDoes Immatics NV reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Immatics NV disclose its ethnicity pay gap?
Sign up for free to unlockDoes Immatics NV disclose cybersecurity risks?
Sign up for free to unlockDoes Immatics NV offer flexible work?
Sign up for free to unlockDoes Immatics NV have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Immatics NV disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Immatics NV conduct supply chain audits?
Sign up for free to unlockDoes Immatics NV disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Immatics NV conduct 360 degree staff reviews?
Sign up for free to unlockDoes Immatics NV disclose the individual responsible for D&I?
Sign up for free to unlockDoes Immatics NV disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Immatics NV disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Immatics NV disclose water use targets?
Sign up for free to unlockDoes Immatics NV have careers partnerships with academic institutions?
Sign up for free to unlockDid Immatics NV have a product recall in the last two years?
Sign up for free to unlockDoes Immatics NV disclose incidents of discrimination?
Sign up for free to unlockDoes Immatics NV allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Immatics NV issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Immatics NV disclose parental leave metrics?
Sign up for free to unlockDoes Immatics NV disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Immatics NV disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Immatics NV disclose the pay ratio of women to men?
Sign up for free to unlockDoes Immatics NV support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Immatics NV disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Immatics NV reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Immatics NV involved in embryonic stem cell research?
Sign up for free to unlockDoes Immatics NV disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Immatics NV disclose its waste policy?
Sign up for free to unlockDoes Immatics NV report according to TCFD requirements?
Sign up for free to unlockDoes Immatics NV disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Immatics NV disclose energy use targets?
Sign up for free to unlockDoes Immatics NV disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Immatics NV have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Immatics NV
These potential risks are based on the size, segment and geographies of the company.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.